Patients with mutations in the RPE65 gene suffer from blindness. In a new Phase 3 study, clinicians have demonstrated that gene therapy, by injecting over 100 billion viral vector genomes into the eyes of these patients, could substantially improve their ability to perceive light, navigate and read.

See the source article by following the link below:
Patients with mutations in the RPE65 gene suffer from blindness. In a new Phase 3 study, clinicians have demonstrated that gene therapy, by injecting over 100 billion viral vector genomes into the eyes of these patients, could substantially improve their ability to perceive light, navigate and read.